Xilio Therapeutics, Inc. (NASDAQ: XLO)

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of tumor-activated immuno-oncology (I-O) therapies to enhance outcomes for patients with cancer. The company's proprietary platform is designed to localize anti-tumor activity within the tumor microenvironment, minimizing systemic side effects. Xilio's pipeline includes XTX101, XTX301, and XTX202, which are being developed to overcome the limitations of current I-O therapies.

Xilio's main business activities revolve around developing tumor-activated I-O molecules that can selectively target the tumor microenvironment, reducing systemic toxicity and improving therapeutic efficacy. The company's products are designed to be inactive until they reach the tumor microenvironment, where they are activated by the unique conditions of the tumor, resulting in localized clinical activity with minimal dose-limiting toxicities.

The company's most advanced product candidates are XTX101, XTX301, and XTX202. XTX101 is an investigational tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells when activated in the tumor microenvironment. XTX301 is an investigational tumor-activated IL-12 designed to potently stimulate anti-tumor immunity and reprogram the tumor microenvironment of poorly immunogenic tumors towards an inflamed or "hot" state. XTX202 is an investigational tumor-activated, beta-gamma biased IL-2 designed to potently stimulate CD8+ effector T cells and natural killer cells without concomitant stimulation of regulatory T cells when activated in the tumor microenvironment.

Xilio's position within the industry is that of a clinical-stage biotechnology company focused on developing novel, tumor-activated I-O therapies. The company's proprietary platform is designed to overcome the limitations of current I-O therapies, including systemic toxicity and limited therapeutic index. Xilio's key competitors in the I-O space are companies such as Bristol-Myers Squibb, Merck & Co., and Roche Holding.

Xilio's customers are primarily oncology patients and their physicians, who are seeking effective and tolerable treatments for various types of cancer. The company's products are designed to be used in combination with other cancer therapies, such as chemotherapy and radiation, to achieve optimal therapeutic outcomes.

In terms of its clinical trials, Xilio has reported preliminary safety data for XTX101, XTX301, and XTX202. For XTX101, the company reported that the recommended Phase 2 dose and schedule of 150 mg Q6W was determined based on the favorable preliminary safety, pharmacokinetic, and pharmacodynamic data. The company also reported that a partial response was observed in a patient with advanced PD-L1 negative NSCLC, including complete resolution of liver metastases.

For XTX301, the company reported that the preliminary Phase 1 dose escalation safety data showed that XTX301 was generally well-tolerated across all dose levels with no dose-limiting toxicities observed in patients. The company also reported that the half-life extension domain was designed to overcome the short circulating half-life of the native cytokine.

For XTX202, the company reported that the initial Phase 1/2 monotherapy data showed that XTX202 was well-tolerated, with no dose-limiting toxicities observed in patients. The company also reported that the removable protease-cleavable protein mask was designed to prevent XTX202 from binding and signaling until the mask was removed by the matrix metalloproteinases (MMPs) that are preferentially active within the tumor microenvironment.

Xilio's proprietary platform technology enables tumor-activated I-O molecules that can effect tumor-activated immunotherapy while minimizing systemic toxicity. The company's patent portfolio includes 18 patent application families related to its business, including four pending Patent Cooperation Treaty patent applications, 14 pending U.S. non-provisional applications, seven issued U.S. patents, and 169 pending foreign applications in various jurisdictions.

The company's trademark portfolio includes two federal trademark registrations for XILIO and XILIO THERAPEUTICS (Class 42) in the United States and a pending federal trademark application for XILIO (Class 5) in the United States.

Xilio's patent prosecution strategy involves filing provisional patent applications, followed by non-provisional patent applications, and then national stage patent applications in various jurisdictions. The company's patent term extensions include patent term restoration and extension under the Hatch-Waxman Act, which allows for a limited extension of up to five years beyond the normal expiration date of the patent.

In addition to patent protection, Xilio also relies on trade secrets, know-how, and other proprietary information to strengthen its competitive position. The company takes steps to protect and preserve its trade secrets and other confidential and proprietary information, including by entering into non-disclosure and invention assignment agreements with parties who have access to its trade secrets or other confidential and proprietary information.

Xilio has entered into several license agreements with third parties, including AskGene, City of Hope, and WuXi Biologics. These agreements grant Xilio exclusive worldwide licenses to specified patent rights and know-how, and impose various diligence and financial payment obligations on Xilio.

Xilio currently contracts with a third-party contract development and manufacturing organization (CDMO) to manufacture its product candidates for preclinical studies and clinical trials, and intends to continue to do so with one or more third parties for future preclinical studies and clinical trials.